Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 9943 results found since Jan 2013.
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
CONCLUSION: Our findings suggested that TPC combination could be a cost-saving option in patients with HER2+BC at high-risk of recurrence.PMID:37573652 | DOI:10.1016/j.breast.2023.08.005
Source: Breast - August 13, 2023 Category: Cancer & Oncology Authors: Alberto Zambelli Marina Cazzaniga Nicla La Verde Elisabetta Munzone Ippazio Cosimo Antonazzo Lorenzo Giovanni Mantovani Serena Di Cosimo Anna Mancuso Daniele Generali Paolo Angelo Cortesi Source Type: research
ASO Visual Abstract: Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node-Negative T1 Triple-Negative Breast Cancer
Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14097-9. Online ahead of print.NO ABSTRACTPMID:37574519 | DOI:10.1245/s10434-023-14097-9
Source: Ann Oncol - August 13, 2023 Category: Cancer & Oncology Authors: Kai Huang James Jakub Emmanuel Gabriel Alvaro Moreno-Aspitia Sarah McLaughlin Source Type: research
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
CONCLUSION: Our findings suggested that TPC combination could be a cost-saving option in patients with HER2+BC at high-risk of recurrence.PMID:37573652 | PMC:PMC10428118 | DOI:10.1016/j.breast.2023.08.005
Source: Breast - August 13, 2023 Category: Cancer & Oncology Authors: Alberto Zambelli Marina Cazzaniga Nicla La Verde Elisabetta Munzone Ippazio Cosimo Antonazzo Lorenzo Giovanni Mantovani Serena Di Cosimo Anna Mancuso Daniele Generali Paolo Angelo Cortesi Source Type: research
Effect of neoadjuvant therapy on serum transforming growth factor- β, squamous cell carcinoma associated antigen, and prognosis in patients with locally advanced esophageal cancer
Cell Mol Biol (Noisy-le-grand). 2023 May 31;69(5):112-118. doi: 10.14715/cmb/2023.69.5.18.ABSTRACTIt was to explore the effect of neoadjuvant therapy (NAT) on serum-related indicators and prognosis of patients with locally advanced esophageal cancer (EC). 400 EC patients were grouped as controls (295 cases, radical EC resection alone) and research group (105 cases, NAT plus radical EC resection). The levels of serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), programmed death-1 (PD-1), PD-2, transforming growth factor-β1 (TGF-β1), and squamous ...
Source: Mol Biol Cell - August 12, 2023 Category: Molecular Biology Authors: Ruirui Zhang Wenze Tian Huanyu Zhao Zhengwei Zhang Jian Wu Su'an Sun Haiyan Liu Source Type: research
ASO Visual Abstract: Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study
Ann Surg Oncol. 2023 Aug 12. doi: 10.1245/s10434-023-14061-7. Online ahead of print.NO ABSTRACTPMID:37573287 | DOI:10.1245/s10434-023-14061-7
Source: Ann Oncol - August 12, 2023 Category: Cancer & Oncology Authors: Gabriella N Tortorello Eric H Li Cimarron E Sharon Kevin L Ma Robert G Maki John T Miura Douglas L Fraker Ronald P DeMatteo Giorgos C Karakousis Source Type: research
Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges
CONCLUSION: Using a tumor marker gene test to personalize an individual's CA19-9 reference range significantly improves diagnostic accuracy.PMID:37566230 | DOI:10.1158/1078-0432.CCR-23-0655
Source: Clinical Cancer Research - August 11, 2023 Category: Cancer & Oncology Authors: Mohamad Dbouk Toshiya Abe Chiho Koi Yohei Ando Helena Saba Elizabeth Abou Diwan Anne Macgregor-Das Amanda L Blackford Evelina Mocci Katie Beierl Ali Dbouk Jin He Richard Burkhart Anne Marie Lennon Lori Sokoll Marcia Irene Canto James R Eshleman Michael Go Source Type: research
